Figure 4.
OX40.ADR T cells preserve cytotoxic antiviral T-cell immunity. (A) Schematic of model setup for panels B-C. Ctrl or OX40.ADR T cells were cocultured with autologous peptide pulsed-lymphoblastoid cell lines (LCLs) (EBV-immortalized lymphoblastoid cell lines pulsed with a mix of EBV, CMV, and AdV peptides) and autologous VSTs. (B) Relative counts of residual peptide pulsed-LCL for specified conditions on day 2 (left) and day 9 (right) post coculture. Counts were normalized to LCL-only conditions. (C) Relative counts of residual VSTs for specified conditions on day 2 post coculture. Counts were normalized to VST-only conditions. In panels B-C, mean ± SD values are shown. Each dot represents data from an individual donor. P values were calculated using 1-way ANOVA followed with Sidak correction. (D) Schematic of model setup for panels E-F. (E) Change of EBV-VST bioluminescence signals overtime. (F) Change of LCL tumor volumes overtime. P value was calculated using 2-way ANOVA followed with Tukey correction. Statistical difference on day 28 is shown. In panels E-F, mean ± SD values are shown. Not significant (ns), P ≥ .05. Ctrl, control nontransduced T cells; FFluc, firefly luciferase; i.v., intravenous injection; s.c., subcutaneous injection.

OX40.ADR T cells preserve cytotoxic antiviral T-cell immunity. (A) Schematic of model setup for panels B-C. Ctrl or OX40.ADR T cells were cocultured with autologous peptide pulsed-lymphoblastoid cell lines (LCLs) (EBV-immortalized lymphoblastoid cell lines pulsed with a mix of EBV, CMV, and AdV peptides) and autologous VSTs. (B) Relative counts of residual peptide pulsed-LCL for specified conditions on day 2 (left) and day 9 (right) post coculture. Counts were normalized to LCL-only conditions. (C) Relative counts of residual VSTs for specified conditions on day 2 post coculture. Counts were normalized to VST-only conditions. In panels B-C, mean ± SD values are shown. Each dot represents data from an individual donor. P values were calculated using 1-way ANOVA followed with Sidak correction. (D) Schematic of model setup for panels E-F. (E) Change of EBV-VST bioluminescence signals overtime. (F) Change of LCL tumor volumes overtime. P value was calculated using 2-way ANOVA followed with Tukey correction. Statistical difference on day 28 is shown. In panels E-F, mean ± SD values are shown. Not significant (ns), P ≥ .05. Ctrl, control nontransduced T cells; FFluc, firefly luciferase; i.v., intravenous injection; s.c., subcutaneous injection.

Close Modal

or Create an Account

Close Modal
Close Modal